News
CODX
3.350
+41.95%
0.990
Co-Diagnostics Faces Nasdaq Delisting After Bid Price Noncompliance
TipRanks · 1d ago
Co-Diagnostics trading resumes
TipRanks · 1d ago
Co-Diagnostics To Be Delisted From Nasdaq Effective Jan 14, 2026, After Failing Minimum $1.00 Bid Price Rule; Plans Hearing While Trading Moves To OTC Pink
Benzinga · 1d ago
Co-Diagnostics trading halted, volatility trading pause
TipRanks · 1d ago
Nasdaq Moves to Delist Co-Diagnostics Inc. Over Bid Price Non-Compliance
Reuters · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/25
TipRanks · 1d ago
CoSara Expands Distributor Network Across India for Co-Diagnostics Inc
Reuters · 2d ago
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
PR Newswire · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/12/25
TipRanks · 2d ago
Weekly Report: what happened at CODX last week (0105-0109)?
Weekly Report · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/9/25
TipRanks · 5d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/8/25
TipRanks · 6d ago
VTI ETF Daily Update — 1/7/25
TipRanks · 01/07 13:06
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/6/25
TipRanks · 01/06 13:26
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/5/25
TipRanks · 01/05 13:44
Weekly Report: what happened at CODX last week (1229-0102)?
Weekly Report · 01/05 10:04
Co-Diagnostics trading halted, news pending
TipRanks · 01/01 00:50
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
NASDAQ · 12/31/2025 15:49
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/30/2025 17:05
Co-Diagnostics Approves Reverse Stock Split to Maintain Listing
TipRanks · 12/30/2025 14:48
More
Webull provides a variety of real-time CODX stock news. You can receive the latest news about Co-Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.